BPG is committed to discovery and dissemination of knowledge
Featured Articles
5/7/2023 9:19:03 AM | Browse: 127 | Download: 335
 |
Received |
|
2022-12-26 04:59 |
|
Peer-Review Started |
|
2022-12-26 05:01 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-02-08 01:17 |
|
Revised |
|
2023-02-17 14:57 |
|
Second Decision |
|
2023-04-13 03:05 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2023-04-13 09:04 |
|
Articles in Press |
|
2023-04-13 09:04 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-04-21 03:27 |
|
Publish the Manuscript Online |
|
2023-05-07 07:47 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Basic Study |
| Article Title |
Establishment and characterization of a new human ampullary carcinoma cell line, DPC-X1
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hao Xu, Chang-Peng Chai, Xin Miao, Huan Tang, Jin-Jing Hu, Hui Zhang and Wen-Ce Zhou |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
82260555 |
| Gansu Provincial Science and Technology Plan |
1606RJZA139 |
| Gansu Provincial Science and Technology Plan |
21JR11RA096 |
| Gansu Provincial Science and Technology Plan |
21JR1RA099 |
| Gansu Provincial Science and Technology Plan |
21JR1RA113 |
| Gansu Health Industry Project |
GSWSKY2020-21 |
| Traditional Chinese Medicine Scientific Research Project of Gansu Province |
GZKP-2020-28 |
| Talent Innovation and Entrepreneurship Project of Lanzhou |
2020-RC-46 |
| Intra-Hospital Fund of the First Hospital of Lanzhou University |
ldyyyn2019-97 |
|
| Corresponding Author |
Hao Xu, Doctor, MD, Associate Chief Physician, Surgeon, The Forth Department of General Surgery, The First Hospital of Lanzhou University, No. 1 Donggang West Road, Lanzhou 730000, Gansu Province, China. amoyxu@126.com |
| Key Words |
Ampullary carcinoma; Cell line; Xenograft; Drug resistance |
| Core Tip |
A new ampullary carcinoma cell line has been established, making up for the shortage of Chinese ampullary carcinoma cell lines. And this is the the first study to report a mixed-type ampullary carcinoma cell line. The cell line inoculated into BALB/c nude mice can quickly form xenograft tumors. It is an excellent model for studying the mechanisms of invasion, metastasis and other mechanisms of ampullary carcinoma. The cell line is sensitive to oxaliplatin and paclitaxel but is naturally resistant to gemcitabine and fluorouracil, which can be used for drug resistance mechanism research and new drug development. |
| Publish Date |
2023-05-07 07:47 |
| Citation |
Xu H, Chai CP, Miao X, Tang H, Hu JJ, Zhang H, Zhou WC. Establishment and characterization of a new human ampullary carcinoma cell line, DPC-X1. World J Gastroenterol 2023; 29(17): 2642-2656 |
| URL |
https://www.wjgnet.com/1007-9327/full/v29/i17/2642.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v29.i17.2642 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
